Evidence map›Paper›PMID 24400649›Full record

ArticleBMC biotechnology2014

Experimental design approach in recombinant protein expression: determining medium composition and induction conditions for expression of pneumolysin from Streptococcus pneumoniae in Escherichia coli and preliminary purification process.

Guillermo Marini, Mateus Dalcin Luchese, Ana Paula Correa Argondizzo, Ana Carolina Magalhães Andrade de Góes, Ricardo Galler, Tito Lívio Moitinho Alves, Marco Alberto Medeiros, Ariane Leites Larentis

Open access · goldAbstract read
In one paragraph

Article in BMC biotechnology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 110 citations in OpenAlex.

  1. Article
  2. Novel processes to obtain pneumococcal surface proteins for vaccines.Applied microbiology and biotechnology · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Guillermo MariniBio-Manguinhos (Instituto de Tecnologia em Imunobiológicos) - Fundação Oswaldo Cruz (FIOCRUZ) - VDTEC (Vice-Diretoria de Desenvolvimento Tecnológico), Av, Brasil 4365, Pavilhão Rockfeller Sala 202 - 21040-360, Manguinhos, Rio de Janeiro, RJ, Brazil. guillermo@peq.coppe.ufrj.br.
Mateus Dalcin Luchese
Ana Paula Correa Argondizzo
Ana Carolina Magalhães Andrade de Góes
Ricardo Galler
Tito Lívio Moitinho Alves
Marco Alberto Medeiros
Ariane Leites Larentis
Fundação Oswaldo Cruz · BRUniversidade Federal do Rio de Janeiro · BREscola Nacional de Saúde Pública · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStreptococcus pneumoniae (S. pneumoniae) causes several serious diseases including pneumonia, septicemia and meningitis. The World Health Organization estimates that streptococcal pneumonia is the cause of approximately 1.9 million deaths of children under five years of age each year. The large number of serotypes underlying the disease spectrum, which would be reflected in the high production cost of a commercial vaccine effective to protect against all of them and the higher level of amino acid sequence conservation as compared to polysaccharide structure, has prompted us to attempt to use conserved proteins for the development of a simpler vaccine. One of the most prominent proteins is pneumolysin (Ply), present in almost all the serotypes known at the moment, which shows an effective protection against S. pneumoniae infections.

resultsWe have cloned the pneumolysin gene from S. pneumoniae serotype 14 and studied the effects of eight variables related to medium composition and induction conditions on the soluble expression of rPly in Escherichia coli (E. coli) and a 28-4 factorial design was applied. Statistical analysis was carried out to compare the conditions used to evaluate the expression of soluble pneumolysin; rPly activity was evaluated by hemolytic activity assay and served as the main response to evaluate the proper protein expression and folding. The optimized conditions, validated by the use of triplicates, include growth until an absorbance of 0.8 (measured at 600 nm) with 0.1 mM IPTG during 4 h at 25°C in a 5 g/L yeast extract, 5 g/L tryptone, 10 g/L NaCl, 1 g/L glucose medium, with addition of 30 μg/mL kanamycin.

conclusionsThis experimental design methodology allowed the development of an adequate process condition to attain high levels (250 mg/L) of soluble expression of functional rPly in E. coli, which should contribute to reduce operational costs. It was possible to recover the protein in its active form with 75% homogeneity.

Indexed as

Bacterial ProteinsBiotechnologyCloning, MolecularData Interpretation, StatisticalEscherichia coliMultivariate AnalysisRecombinant ProteinsReproducibility of ResultsResearch DesignStreptococcus pneumoniaeStreptolysinsBacterial ProteinsplY protein, Streptococcus pneumoniaeRecombinant ProteinsStreptolysins

Identifiers

PMID24400649
PMCPMC3897902
OpenAlexW1989341870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.